A Discussion with Two Authors of the Family Heart Foundation Research Paper on PCSK9 Inhibitors

New research from the Family Heart Foundation shows access to PCSK9 inhibitors (PCSK9i) has slightly improved, but there is still a major barrier to these LDL cholesterol lowering drugs. Vice President of Science and Research Diane MacDougall and cardiologist and clinical lipidologist Dr. Seth Baum discuss the nuances and impact of this important research.